OrthoLogic's stock got a bump this morning after researchers announced a late-stage study of its drug Chrysalin indicated that it shortened the amount of time fractured wrists had to stay immobilized. The reduction in immobilization time occurred for a subset of osteopenic women with unstable wrist fractures.
"We continue to learn more about the basic science, mechanism of action, biological activity and potential clinical utility of Chrysalin," said Randolph C. Steer, M.D., Ph.D., president of OrthoLogic. "This is among the largest clinical trials in fracture repair ever conducted, and the database we have built from the study has yielded some intriguing results."
- check out the release
- here's the AP report on the study